News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]

Zenas BioPharma (ZBIO) was downgraded by Wall Street Zen from "hold"

Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".

Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.

Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.

3/16/2026

07:00 am

zbio

-2.1%

MISS

11/12/2025

07:05 am

zbio

1.7%

MISS

Form DEFA14A Zenas BioPharma, Inc.

Form ARS Zenas BioPharma, Inc. For: Dec 31

Form DEF 14A Zenas BioPharma, Inc. For: May 11

Form S-8 Zenas BioPharma, Inc.

Form 10-K Zenas BioPharma, Inc. For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}